Trading Statement

Allergy Therapeutics PLC
14 July 2006



        Allergy Therapeutics plc, "Allergy Therapeutics" or "the Company"
                                        
                                  Trading update

Allergy Therapeutics plc, the specialist pharmaceuticals company focused on
allergy vaccination, today issues the following pre-close trading update
relating to the financial year ended 30 June 2006.


The preliminary results for the year will be announced on 12 September 2006.
Sales for the year are expected to be approximately £23.5m, in line with current
market expectations.


Allergy Therapeutics has made excellent progress with its clinical programmes
during the year. These programmes are focused on the development of the
Company's lead product, Pollinex(R) Quattro, an innovative four-shot vaccination
for allergy sufferers.


Allergy Therapeutics is now in an excellent position, having:

-   one product ready for submission for registration in Canada - Pollinex
    Quattro Ragweed

-   one product in Phase III studies worldwide - Pollinex Quattro Grass

    o Clarity on the crucially important 'route to registration' established

-   two products at the Phase II/III interface worldwide - Pollinex Quattro Tree
    and Pollinex Quattro Ragweed

-   the financial resources to continue the development programme independently

-   the clinical results to explore options for partnering from a position of
    strength


                                     -ends-


Allergy Therapeutics                                                01903 844720

Keith Carter, Chief Executive

Ian Postlethwaite, Finance Director


Bell Pottinger                                                     020 7861 3232

Dan de Belder / Emma Charlton




                      This information is provided by RNS
            The company news service from the London Stock Exchange